SEL-403 for Pancreatic Cancer and Mesothelioma

view our pipeline

SEL-403 consists of a recombinant immunotoxin candidate (LMB-100), a potent and targeted anti-tumor agent, co-administered with SVP-Rapamycin to prevent anti-drug antibodies (ADAs) to the immunotoxin. Selecta licensed LMB-100 from the National Cancer Institute (NCI) in 2017, and Selecta and NCI are now preparing a Phase 1b clinical trial to assess the ability to treat mesothelioma by enabling patients to receive multiple treatment cycles of SEL-403.




Back to Top